The cardiothoracic surgeon covers the newly published New England Journal of Medicine results from Lilly's phase 3 retatrutide trial.
Recap by typeshit. Post by Facebook on Facebook.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
A Facebook explainer says that as of October 2026 retatrutide remains an investigational drug, not cleared by the FDA for any indication.
She covers birth control, thyroid and blood pressure drugs, including why tirzepatide and Foundayo users may need backup contraception after dose increases.
Loading…